(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.01%) $78.37
(0.59%) $2.22
(-0.06%) $2 322.80
(-0.29%) $27.47
(0.03%) $988.70
(0.07%) $0.930
(0.05%) $10.91
(0.07%) $0.800
(0.12%) $91.45
3.82% HKD 6.25
Live Chart Being Loaded With Signals
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China...
Stats | |
---|---|
Dzisiejszy wolumen | 1.17M |
Średni wolumen | 786 395 |
Kapitalizacja rynkowa | 5.00B |
EPS | HKD0 ( 2024-03-28 ) |
Następna data zysków | ( HKD0 ) 2024-05-31 |
Last Dividend | HKD0.300 ( 2023-06-08 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 5.90 |
ATR14 | HKD0.00700 (0.11%) |
Wolumen Korelacja
Consun Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Consun Pharmaceutical Korelacja - Waluta/Towar
Consun Pharmaceutical Finanse
Annual | 2023 |
Przychody: | HKD2.59B |
Zysk brutto: | HKD1.92B (74.19 %) |
EPS: | HKD0.990 |
FY | 2023 |
Przychody: | HKD2.59B |
Zysk brutto: | HKD1.92B (74.19 %) |
EPS: | HKD0.990 |
FY | 2022 |
Przychody: | HKD2.34B |
Zysk brutto: | HKD1.76B (75.35 %) |
EPS: | HKD0.860 |
FY | 2021 |
Przychody: | HKD2.04B |
Zysk brutto: | HKD1.53B (74.70 %) |
EPS: | HKD0.740 |
Financial Reports:
No articles found.
Consun Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.300 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0480 | 2014-09-25 |
Last Dividend | HKD0.300 | 2023-06-08 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 19 | -- |
Total Paid Out | HKD2.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.31 | -- |
Div. Sustainability Score | 8.45 | |
Div.Growth Potential Score | 5.71 | |
Div. Directional Score | 7.08 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2283.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1268.HK | Ex Dividend Knight | 2023-09-20 | Semi-Annually | 0 | 0.00% | |
0317.HK | Ex Dividend Junior | 2023-05-29 | Sporadic | 0 | 0.00% | |
6066.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
1820.HK | Ex Dividend Junior | 2023-10-20 | Semi-Annually | 0 | 0.00% | |
0855.HK | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
0004.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
2601.HK | Ex Dividend Knight | 2023-05-30 | Annually | 0 | 0.00% | |
1385.HK | Ex Dividend Junior | 2023-06-27 | Sporadic | 0 | 0.00% | |
0455.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.303 | 1.500 | 3.94 | 5.91 | [0 - 0.5] |
returnOnAssetsTTM | 0.142 | 1.200 | 5.25 | 6.30 | [0 - 0.3] |
returnOnEquityTTM | 0.227 | 1.500 | 8.59 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.416 | -1.000 | 5.84 | -5.84 | [0 - 1] |
currentRatioTTM | 2.86 | 0.800 | 0.692 | 0.554 | [1 - 3] |
quickRatioTTM | 2.57 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.838 | 1.500 | 0.898 | 1.347 | [0.2 - 2] |
debtRatioTTM | 0.0929 | -1.500 | 8.45 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.018 | 2.00 | 9.66 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.953 | 2.00 | 9.52 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.141 | -1.500 | 9.44 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.968 | 0.968 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.319 | 1.000 | 5.62 | 5.62 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.601 | 1.000 | 2.22 | 2.22 | [0.2 - 2] |
assetTurnoverTTM | 0.470 | 0.800 | -0.198 | -0.159 | [0.5 - 2] |
Total Score | 8.45 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.69 | 1.000 | 9.53 | 0 | [1 - 100] |
returnOnEquityTTM | 0.227 | 2.50 | 9.10 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.953 | 2.00 | 9.68 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 8.11 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.018 | 2.00 | 9.66 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.416 | 1.500 | 5.84 | -5.84 | [0 - 1] |
pegRatioTTM | -0.0747 | 1.500 | -3.83 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.316 | 1.000 | 4.60 | 0 | [0.1 - 0.5] |
Total Score | 5.71 |
Consun Pharmaceutical
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej